Balanced Placebo Design, Active Placebos, and Other Design Features for Identifying, Minimizing and Characterizing the Placebo Response

Placebo and Pain: From Bench to Bedside

Volumn , Issue , 2013, Pages 159-173

  Enck, Paul ^a   Weimer, Katja ^a   Klosterhalfen, Sibylle ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Blinding; Control group; Placebo effect; Randomization; Trial designs

Indexed keywords

EID: 84902423204     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397928-5.00016-7     Document Type: Chapter

References (104)

1. Enck P., Bingel U., Schedlowski M., Rief M. Minimize, maximize or personalize: what to do with the placebo response in medicine?. Nat Rev Drug Disc 2013, 12:191-204.
2. Staud R., Price D.D. Role of placebo factors in clinical trials with special focus on enrichment designs. Pain 2008, 139:479-480.
3. Iovieno N., Papakostas G.I. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry 2012, 73:1300-1306.
4. Enck P., Horing B., Weimer K., Klosterhalfen S. Placebo responses and placebo effects in functional bowel disorders. Eur J Gastroenterol Hepatol 2012, 24:1-8.
5. Enck P., Benedetti F., Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008, 59:195-206.
6. Colloca L., Lopiano L., Lanotte M., Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurol 2004, 3:679-684.
7. Benedetti F., Carlino E., Pollo A. Hidden administration of drugs. Clin Pharmacol Ther 2011, 90:651-661.
8. Hrobjartsson A., Boutron I. Blinding in randomized clinical trials: imposed impartiality. Clin Pharmacol Ther 2011, 90:732-736.
9. Lee S., Walker J.R., Jakul L., Sexton K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 2004, 19:10-19.
10. US Department of Health and Human Services, Food and Drug Administration. Guidance for Índustry. E 10 Choice of control groups and related issues in clinical trials. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). 2001 Accessed 24.06.12. .
11. Madsen L.G., Bytzer P. Review article: single subject trials as a research instrument in gastrointestinal pharmacology. Aliment Pharmacol Ther 2002, 16:189-196.
12. Moncrieff J., Wessely S., Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004, CD003012.
13. Woods S.W., Gueorguieva R.V., Baker C.B., Makuch R.W. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 2005, 62:961-970.
14. Rao S., Lembo A.J., Shiff S.J., et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012, 107:1714-1724.
15. Iovieno N., Papakostas G.I. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?. J Clin Psychiatry 2012, 73:676-683.
16. Mallinckrodt C., Chuang-Stein C., McSorley P., et al. A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant. Pharm Stat 2007, 6:9-22.
17. Staskin D.R., Michel M.C., Sun F., et al. The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms. J Urol 2012, 187:1721-1726.
18. Ivanova A., Tamura R.N. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Stat Methods Med Res 2011, (in press).
19. King M., Nazareth I., Lampe F., et al. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. Health Technol Assess 2005, 9:1-186. iii-iv.
20. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979, 300:1242-1245.
21. Weijer C., Grimshaw J.M., Eccles M.P., et al. Ottawa Ethics of Cluster Randomized Trials Consensus Group. The Ottawa statement on the ethical design and conduct of cluster randomized trials. PLoS Med 2012, 9:e1001346.
22. Rief W., Nestoriuc Y., Weiss S., et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009, 118:1-8.
23. Hrobjartsson A., Gotzsche P.C. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010, CD003974.
24. Kirsch I., Deacon B.J., Huedo-Medina T.B., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:e45.
25. Nijs J., Inghelbrecht E., Daenen L., et al. Recruitment bias in chronic pain research: whiplash as a model. Clin Rheumatol 2011, 30:1481-1489.
26. Kaptchuk T.J., Kelley J.M., Deykin A., et al. Do 'placebo responders' exist?. Contemp Clin Trials 2008, 29:587-595.
27. Stone D.A., Kerr C.E., Jacobson E., et al. Patient expectations in placebo-controlled randomized clinical trials. J Eval Clin Pract 2005, 11:77-84.
28. Pressman A., Avins A.L., Neuhaus J., et al. Adherence to placebo and mortality in the Beta Blocker Evaluation of Survival Trial (BEST). Contemp Clin Trials 2012, 33:492-498.
29. Boehmer J., Yong P. How well does blinding work in randomized controlled trials?: a counterpoint. Clin Pharmacol Ther 2009, 85:463-465.
30. Cepeda M.S., Berlin J.A., Gao C.Y., et al. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis. Pain Med 2012, 13:575-595.
31. Kirsch I. Are drug and placebo effects in depression additive?. Biol Psychiatry 2000, 47:733-735.
32. Hill A.B. Suspended judgement: memories of the British streptomycin trial in tuberculosis. The first randomized clinical trial. Contemp Clin Trials 1990, 11:77-79.
33. Muthén B., Brown H.C. Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med 2009, 28:3363-3385.
34. Petrovic P., Kalso E., Petersson K.M., et al. A prefrontal non-opioid mechanism in placebo analgesia. Pain 2010, 150:59-65.
35. Rief W., Glombiewski J.A. The hidden effects of blinded, placebo-controlled randomized trials: An experimental investigation. Pain 2012, 153:2473-2477.
36. Kelemen W.L., Kaighobadi F. Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design. Exp Clin Psychopharmacol 2007, 15:93-101.
37. Metrik J., Rohsenow D.J., Monti P.M., et al. Effectiveness of a marijuana expectancy manipulation: piloting the balanced-placebo design for marijuana. Exp Clin Psychopharmacol 2009, 17:217-225.
38. Papakostas G.I., Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009, 19:34-40.
39. Lidstone S.C., Schulzer M., Dinelle K., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiat 2010, 67:857-865.
40. Fiorillo C.D., Tobler P.N., Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons. Science 2003, 299:1898-1902.
41. Weimer K., Horing B., Stürmer J., et al. Nicotine expectancy differentially affects reaction time in healthy non-smokers and smokers depending on gender. Exp Clin Psychopharmacol 2013, 21:181-187.
42. Suchman A.L., Ader R. Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 1992, 52:372-377.
43. Colloca L., Benedetti F. How prior experience shapes placebo analgesia. Pain 2006, 124:126-133.
44. Miller F.G., Wendler D., Swartzman L.C. Deception in research on the placebo effect. PLoS Med 2005, 2:e262.
45. Enck P., Klosterhalfen S., Zipfel S. Novel study designs to investigate the placebo response. BMC Med Res Methodol 2011, 11:90.
46. Behzadi S.S., Toegel S., Viernstein H. Innovations in coating technology. Recent Pat Drug Deliv Formul 2008, 2:209-230.
47. Twomey K., Marchesi J.R. Swallowable capsule technology: current perspectives and future directions. Endoscopy 2009, 41:357-362.
48. D'Agostino R.B. The delayed-start study design. N Engl J Med 2009, 361:1304-1306.
49. Fernandez-Becker N.Q., Moss A.C. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs 2008, 68:1089-1103.
50. Edward S.J., Stevens A.J., Braunholtz D.A., et al. The ethics of placebo-controlled trials: a comparison of inert and active placebo controls. World J Surg 2005, 29:610-614.
51. Moncrieff J., Wessely S., Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004, CD003012.
52. Campbell M.K., Entwistle V.A., Cuthbertson B.H., et al. KORAL study group. Developing a placebo-controlled trial in surgery: issues of design, acceptability and feasibility. Trials 2011, 12:50.
53. Moseley J.B., O'Malley K., Petersen N.J., et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002, 347:81-88.
54. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719.
55. Frank S.A., Wilson R., Holloway R.G., et al. Ethics of sham surgery: perspective of patients. Mov Disord 2008, 23:63-68.
56. Landau W. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology 2006, 66:1788-1789.
57. Enck P., Klosterhalfen S., Zipfel S. Acupuncture, psyche and the placebo response. Auton Neurosci 2010, 157:68-73.
58. Moffet H.H. Sham acupuncture may be as efficacious as true acupuncture: a systematic review of clinical trials. J Altern Complement Med 2009, 15:213-216.
59. Lundeberg T., Lund I., Sing A., Näslund J. Is placebo acupuncture what it is intended to be?. Evid Based Complement Alternat Med 2011, 2011:932407.
60. Haake M., Müller H.H., Schade-Brittinger C., et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med 2007, 167:1892-1898.
61. Lundeberg T., Lund I., Näslund J., Thomas M. The Emperors sham - wrong assumption that sham needling is sham. Acupunct Med 2008, 26:239-242.
62. Lund I., Näslund J., Lundeberg T. Minimal acupuncture is not a valid placebo control in randomised controlled trials of acupuncture: a physiologist's perspective. Chin Med 2009, 4:1.
63. Streitberger K., Kleinhenz J. Introducing a placebo needle into acupuncture research. Lancet 1998, 352:364-365.
64. Tough E.A., White A.R., Richards S.H., et al. Developing and validating a sham acupuncture needle. Acupunct Med 2009, 27:118-122.
65. Takakura N., Yajima H. A double-blind placebo needle for acupuncture research. BMC Complement Altern Med 2007, 7:31.
66. McManus C.A., Schnyer R.N., Kong J., et al. Sham acupuncture devices-practical advice for researchers. Acupunct Med 2007, 25:36-40.
67. Takakura N., Yajima H. A placebo acupuncture needle with potential for double blinding - a validation study. Acupunct Med 2008, 26:224-230.
68. White P., Lewith G., Hopwood V., Prescott P. The placebo needle, is it a valid and convincing placebo for use in acupuncture trials? A randomised, single-blind, cross-over pilot trial. Pain 2003, 106:401-409.
69. Kaptchuk T.J., Stason W.B., Davis R.B., et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 2006, 332:391-397.
70. Lindström D., Sundberg-Petersson I., Adami J., Tönnesen H. Disappointment and drop-out rate after being allocated to control group in a smoking cessation trial. Contemp Clin Trials 2010, 31:22-26.
71. Boutron I., Estellat C., Guittet L., et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med 2006, 3:e425.
72. Machado L.A., Kamper S.J., Herbert R.D., et al. Imperfect placebos are common in low back pain trials: a systematic review of the literature. Eur Spine J 2008, 17:889-904.
73. Madsen M.V., Gøtzsche P.C., Hróbjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. BMJ 2009, 338:a3115.
74. Ney P.G., Collins C., Spensor C. Double blind: double talk or are there ways to do better research?. Med Hypotheses 1986, 21:119-126.
75. Hróbjartsson A., Forfang E., Haahr M.T., et al. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 2007, 36:654-663.
76. Boehmer J., Yong P. How well does blinding work in randomized controlled trials?: a counterpoint. Clin Pharmacol Ther 2009, 85:463-465.
77. Krogsbøll L.T., Hróbjartsson A., Gøtzsche P.C. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 2009, 9:1.
78. Moffet H.H. Traditional acupuncture theories yield null outcomes: a systematic review of clinical trials. J Clin Epidemiol 2008, 61:741-747.
79. Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001, 344:1594-1602.
80. Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004, 256:91-100.
81. Saarto T., Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007, CD005454.
82. Quilici S., Chancellor J., Löthgren M., et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009, 9:6.
83. Rutherford B.R., Sneed J.R., Roose S.P. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 2009, 78:172-181.
84. De Allegri M., Pokhrel S., Becher H., et al. Step-wedge cluster-randomised community-based trials: an application to the study of the impact of community health insurance. Health Res Policy Syst 2008, 6:10.
85. Enck P., Grundy D., Klosterhalfen S. A novel placebo-controlled clinical study design without ethical concerns - the free choice paradigm. Med Hypotheses 2012, 79:880-882.
86. Rosenberger W.F., Lachin J.M. The use of response-adaptive designs in clinical trials. Contemp Clin Trials 1993, 14:471-484.
87. Vray M., Girault D., Hoog-Labouret N., et al. Methodology for small clinical trials. Therapie 2004, 59:273-286.
88. Zhang L., Rosenberger W.F. Response-adaptive randomization for clinical trials with continuous outcomes. Biometrics 2006, 62:562-569.
89. Enck P., Klosterhalfen S., Weimer K., et al. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 2011, 366:1889-1895.
90. McCann S.K., Campbell M.K., Entwistle V.A. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials 2010, 11:31.
91. Ehni H.J., Wiesing U. International ethical regulations on placebo-use in clinical trials: a comparative analysis. Bioethics 2008, 22:64-74.
92. Rief W., Bingel U., Schedlowski M., Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 2011, 90:722-726.
93. Weimer K., Gulewitsch M.D., Schlarb A.A., et al. Placebo effects in children: a review. Pediat Res 2013, 10.1038/pr.2013.66.
94. Workshop on Ethical and Regulatory Issues in Global Pediatric Trials 2009 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health Office of Pediatric Therapeutics September 20-22, 2009, US Food and Drug Administration, Rockville, MD.
95. Committee on Drugs, American Academy of Pediatrics Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995, 95:286-294.
96. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 27.12.2006, L378/1.
97. Miller F.G., Wendler D., Wilfond B. When do the federal regulations allow placebo-controlled trials in children?. J Pediatr 2003, 142:102-107.
98. Derivan A.T., Leventhal B.L., March J., et al. The ethical use of placebo in clinical trials involving children. J Child Adolesc Psychopharmacol 2004, 14:169-174.
99. Yan E.G., Munir K.M. Regulatory and ethical principles in research involving children and individuals with developmental disabilities. Ethics Behav 2004, 14:31-49.
100. Roth-Cline M., Gerson J., Bright P., et al. Ethical considerations in conducting pediatric research. Handb Exp Pharmacol 2011, 205:219-244.
101. Martin A.L., Katz J. Inclusion of authorized deception in the informed consent process does not affect the magnitude of the placebo effect for experimentally induced pain. Pain 2010, 149:208-215.
102. Dowrick C.F., Hughes J.G., Hiscock J.J., et al. Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants. BMC Health Serv Res 2007, 7. 64.4.
103. Shahidi J. Not telling the truth: circumstances leading to concealment of diagnosis and prognosis from cancer patients. Eur J Cancer Care (Engl) 2010, 19:589-593.
104. Kaptchuk T.J., Friedlander E., Kelley J.M., et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010, 5:e15591.